<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235910</url>
  </required_header>
  <id_info>
    <org_study_id>10-0746</org_study_id>
    <nct_id>NCT01235910</nct_id>
  </id_info>
  <brief_title>Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation</brief_title>
  <official_title>Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the blood pressure
      medication, aliskiren, in heart transplant patients. In terms of safety, the investigators
      will evaluate the blood levels of aliskiren and determine if aliskiren alters the blood
      levels of the anti-rejection medication, cyclosporine, in these patients. In terms of
      efficacy, the investigators will determine how well aliskiren lowers blood pressure in heart
      transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension is a major complication following cardiac transplantation, with a prevalence of
      93% at 5 years post-transplant. Post-cardiac transplant hypertension is due to multiple
      factors such as use of cyclosporine, chronic kidney disease, and denervation. Hypertension in
      this population is difficult to treat, and most patients require therapy with multiple
      antihypertensive agents in order to achieve adequate blood pressure control. Aliskiren, a
      direct renin inhibitor, is a novel antihypertensive agent with a unique mechanism of action
      and potent blood pressure-lowering effects. As such, aliskiren is an attractive treatment
      option for post-cardiac transplant hypertension. This study will characterize the
      pharmacokinetic drug-drug interaction profile, pharmacodynamics, and safety of aliskiren 75
      mg daily (low-dose) and 150 mg daily, when given in combination with cyclosporine, in cardiac
      transplant patients.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was stopped early due to difficulty finding patients who met I/E criteria.
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-normalized Cyclosporine Area Under the Plasma Concentration-time Curve (AUC)</measure>
    <time_frame>7 days, 14 days, 30 days (End of Study)</time_frame>
    <description>The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any cyclosporine PK (e.g.(AUCs) for this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aliskiren Plasma Concentrations</measure>
    <time_frame>2 weeks</time_frame>
    <description>Maximum plasma concentration; area under the concentration-time curve, half-life, oral clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hypertension</condition>
  <condition>Cardiac Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tekturna (aliskiren)</other_name>
    <other_name>Neoral (cyclosporine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  6 months or more since cardiac transplant

          -  Clinically stable from a transplant perspective

          -  Maintained on a stable immunosuppressant regimen containing cyclosporine + an
             antiproliferative agent (e.g., azathioprine, mycophenolate), +/- an oral steroid

          -  Hypertension, as defined by a seated average systolic blood pressure of ≥ 140 mm Hg
             and a seated average diastolic blood pressure of ≥ 90 mm Hg, based on 3 separate
             measurements, spaced 2 minutes apart.

        Exclusion Criteria:

          -  Clinical instability from a cardiac transplant perspective

          -  Contraindications to aliskiren therapy

          -  Conditions that may increase the risk of aliskiren adverse effects

          -  Severe hypertension

          -  Concomitant medications known to increase or decrease aliskiren plasma exposure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina L Aquilante, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2010</study_first_posted>
  <results_first_submitted>December 10, 2014</results_first_submitted>
  <results_first_submitted_qc>July 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2015</results_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Cardiac transplantation</keyword>
  <keyword>Aliskiren</keyword>
  <keyword>Cyclosporine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
Aliskiren: Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
Aliskiren: Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose-normalized Cyclosporine Area Under the Plasma Concentration-time Curve (AUC)</title>
        <description>The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any cyclosporine PK (e.g.(AUCs) for this study.</description>
        <time_frame>7 days, 14 days, 30 days (End of Study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
Aliskiren: Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-normalized Cyclosporine Area Under the Plasma Concentration-time Curve (AUC)</title>
          <description>The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any cyclosporine PK (e.g.(AUCs) for this study.</description>
          <units>ng*h/ml/mg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Values are not available for this measure. Study was stopped due to difficulty finding patients meeting strict inclusion criteria. One patient was started on the study drug. Therefore, we did not analyze any aliskiren PK (e.g. AUC) in this study.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aliskiren Plasma Concentrations</title>
        <description>Maximum plasma concentration; area under the concentration-time curve, half-life, oral clearance</description>
        <time_frame>2 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <time_frame>2 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
Aliskiren: Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was stopped due to difficulty finding patients who met the strict inclusion/exclusion criteria. Only one patient was started on study drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Aquilante, Pharm.D.</name_or_title>
      <organization>University of Colorado</organization>
      <phone>303-724-6126</phone>
      <email>christina.aquilante@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

